Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 59 Carcinoma, Hepatocellular 46 Colorectal Neoplasms 33 Stomach Neoplasms 31 Esophageal Squamous Cell Carcinoma 27 Squamous Cell Carcinoma of Head and Neck 20 Esophageal Neoplasms 14 Small Cell Lung Carcinoma 13 Neoplasm Metastasis 13 Lung Neoplasms 13 Rectal Neoplasms 12 Head and Neck Neoplasms 12 Advanced Solid Tumor 12 Triple Negative Breast Neoplasms 11 Cholangiocarcinoma 11 Nasopharyngeal Carcinoma 10 Melanoma 10 Uterine Cervical Neoplasms 9 Recurrence 9 Neoplasms 9 Colonic Neoplasms 9 Pancreatic Neoplasms 7 Urinary Bladder Neoplasms 6 Solid Tumor 6 Carcinoma, Transitional Cell 6 Breast Neoplasms 6 Sarcoma 5 Lymphoma, Extranodal NK-T-Cell 5 Lymphoma 5 Hodgkin Disease 5

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

MCRC × tislelizumab × Clear all

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡